chlorpheniramine polistirex; codeine polistirex - Profile

What are the generic drug sources for chlorpheniramine polistirex; codeine polistirex and what is the scope of freedom to operate?

Chlorpheniramine polistirex; codeine polistirex is the generic ingredient in three branded drugs marketed by Lannett Co Inc, Fisons, and Tris Pharma Inc, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Chlorpheniramine polistirex; codeine polistirex has twenty-one patent family members in fourteen countries.

Summary for chlorpheniramine polistirex; codeine polistirex

International Patents:	21
US Patents:	2
Tradenames:	3
Applicants:	3
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for chlorpheniramine polistirex; codeine polistirex

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for chlorpheniramine polistirex; codeine polistirex

Constraining patent/regulatory exclusivity:

8,790,700

Dosage:

SUSPENSION, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for chlorpheniramine polistirex; codeine polistirex

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	CODEPREX	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	021369-001	Jun 21, 2004		DISCN	No	No
Fisons	PENNTUSS	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018928-001	Aug 14, 1985		DISCN	No	No
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,790,700		Y
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,062,667		Y

Expired US Patents for chlorpheniramine polistirex; codeine polistirex

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fisons	PENNTUSS	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018928-001	Aug 14, 1985	4,221,778

International Patents for chlorpheniramine polistirex; codeine polistirex

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2428205	Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
Japan	2009530298
China	102488652	Modified release formulations containing drug-ion exchange resin complexes
Denmark	2018160

Chlorpheniramine polistirex; codeine polistirex Market Analysis and Financial Projection

Last updated: February 4, 2026

What is the investment outlook for chlorpheniramine polistirex and codeine polistirex?

Chlorpheniramine polistirex and codeine polistirex are extended-release formulations of antihistamines and opioids, primarily used to treat cough and cold symptoms. Their market dimensions, developmental pipeline, and regulatory settings influence their investment potential.

What are the market fundamentals for chlorpheniramine polistirex and codeine polistirex?

Market Size and Trends

• The global cough and cold medication market was valued at about $13.6 billion in 2022 and is expected to grow at a CAGR of approximately 4% through 2030 [1].
• Fixed-dose combination products like chlorpheniramine polistirex and codeine polistirex account for an estimated 20-25% of this market.
• Extended-release formulations offer dosing convenience and increased patient compliance. Their adoption is rising, especially in North America and Europe where regulatory barriers are lower.
• Prescription usage primarily occurs in adult markets; pediatric administration of codeine-based products has significantly declined due to safety concerns.

Key Players and Product Availability

• Limited number of branded formulations available globally; most markets rely on adaptations of generic formulations.
• Major pharmaceutical companies such as Pfizer and Johnson & Johnson hold licenses for codeine-based formulations, though some markets restrict codeine use due to regulatory issues.
• Chlorpheniramine polistirex formulations are often off-patent; generics dominate the market.

Regulatory Environment

• The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have issued warnings or restrictions for codeine-containing cough medicines, especially in pediatric populations.
• In the U.S., the FDA classifies codeine as a controlled substance (Schedule V), with approval limited to specific indications.
• Countries increasingly request post-marketing surveillance and risk management plans for opioids, including codeine.

Patent and Lifecycle Considerations

• Many formulations are off-patent, reducing exclusivity. Innovative delivery systems or combination products could extend brand lifecycle.
• No recent major patent filings or exclusivity extensions observed in the last 2 years.

What are the R&D and regulatory hurdles?

• The opioid crisis has driven tighter regulation, impacting sales and new development of codeine-based products.
• Safety concerns over respiratory depression and dependence have led to negative regulatory action and declining prescriber acceptance in some markets.
• Extended-release formulations must demonstrate significant benefit over existing therapies to justify additional approval, particularly in pediatric use.

What does the competitive landscape look like?

Aspect	Description
Manufacturing	Mostly generic manufacturing; low barrier to entry
Innovation	Limited; focus on combination products and delivery systems
Regulatory Pressure	Increasing; risk of market restrictions on opioids
Market Penetration	Saturated in mature markets; growth potential in emerging markets

What are the investment risks?

• Regulatory restrictions on codeine and safety concerns limit market expansion.
• Declining prescribed volume because of increased awareness and regulation.
• High competition from newer non-opioid cough suppressants and antihistamines.
• Limited patent protection reduces potential for premium pricing.

What are the opportunities?

• Development of reformulated products with lower abuse potential.
• Expansion into emerging markets with rising demand for cough and cold remedies.
• Innovative delivery technologies that improve safety profile.
• Focus on combination therapies with novel agents.

Key Takeaways

• The market for chlorpheniramine polistirex and codeine polistirex is mature; growth relies on new formulations, regulatory navigation, and emerging markets.
• Regulatory pressures, especially on opioids, constrain future product approvals and sales.
• Generics dominate, making profit margins slim for branded formulations.
• Safety concerns and public health policies continue to influence prescribing patterns and market availability.
• Innovation centers on delivery and safety, not on active ingredient efficacy or patent protection.

5 FAQs

1. How does regulation impact investment in codeine-containing formulations?
Regulatory agencies impose restrictions due to abuse potential and safety concerns, leading to market limitations, fewer approvals, and declining sales in some regions.

2. Are there new development opportunities for chlorpheniramine polistirex?
Yes, especially in developing delivery systems that reduce side effects or enhance compliance, which could attract niche markets or new formulations.

3. What is the outlook on generic versus branded formulations?
Generics dominate due to low entry barriers. Branded products face pressure from low-cost competitors and regulatory hurdles.

4. How significant is market growth in emerging markets?
Emerging markets are bonafide growth areas due to rising disposable incomes and demand for cough/cold remedies, but regulatory landscapes vary.

5. What are the implications of the opioid crisis on future formulations?
They restrict development and sales of codeine products. Focus shifts to non-opioid alternatives or reformulated opioids with lower abuse potential.

References

1. Research and Markets. (2022). Global Cough and Cold Medicine Market Report.